SSA
FBRX icon

Schonfeld Strategic Advisors’s Forte Biosciences FBRX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-920
Closed -$68K – 2264
2021
Q3 		$68K Buy
+920
New +$510K ﹤0.01% 1973
2021
Q2 		– Sell
-406
Closed -$347K – 2047
2021
Q1 		$347K Buy
+406
New +$332K ﹤0.01% 1279
2020
Q4 		– Sell
-196
Closed -$237K – 1653
2020
Q3 		$237K Buy
+196
New +$130K ﹤0.01% 1168
2019
Q3 		– Sell
-107
Closed -$267K – 1081
2019
Q2 		$267K Buy
+107
New +$317K 0.01% 814

Other funds holding FBRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Schonfeld Strategic Advisors's FBRX Position: Q4 2021 in Review

Schonfeld Strategic Advisors sold out of Forte Biosciences (FBRX) in Q4 2021, closing a stake of 920 shares — an estimated $68K sold.

Schonfeld Strategic Advisors first reported a position in FBRX in Q2 2019 and held it in 4 quarters. The position peaked at $347K in Q1 2021. 52 funds tracked by Wall St. Rank hold FBRX as of Q4 2021.

  • Schonfeld Strategic Advisors reported no remaining Forte Biosciences position as of Q4 2021 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 920 Forte Biosciences shares in Q4 2021, an estimated $68K.
  • Schonfeld Strategic Advisors first reported a position in Forte Biosciences in Q2 2019 and held it in 4 quarters.
  • Schonfeld Strategic Advisors's Forte Biosciences position peaked at $347K in Q1 2021.
  • 52 funds tracked by Wall St. Rank held Forte Biosciences as of Q4 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.